Discover 3,059 paid clinical trials in Brockton, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
for
Squamous Cell Carcinoma of Head and Neck
Location: Boston MA, New Haven CT, New Brunswick NJ, Baltimore MD,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06385080
Phase 1, Phase 2, Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
for
Breast Cancer, Breast Cancer Metastatic,
Location: Boston MA, Buffalo NY, Canton OH, Durham NC, Detroit MI,
Sponsor: Incyclix Bio
Sex: All
Age: 18+
Code: NCT05735080
Phase 1, Phase 2, Recruiting
ECA-enhanced Document Explanation RCT
for
Healthy
Location: Boston MA
Sponsor: Northeastern University
Sex: All
Age: 18+
Code: NCT06435819
Recruiting
Healthy Aging as Black Adults, In It Together: a Comparative Effectiveness Study of Chronic Pain and Cognitive Decline
for
Chronic Pain, Physical Activity, Older Adults,
Location: Boston MA
Sponsor: Massachusetts General Hospital
Sex: All
Age: 50+
Code: NCT06246929
Recruiting
Overcoming the Barriers to Effective Transcranial Temporal Interference Stimulation in Humans
for
Healthy Adult Participants
Location: Boston MA
Sponsor: Northeastern University
Sex: All
Age: 18 - 65
Code: NCT07593859
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
for
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
Location: Boston MA, Fairfax VA, Canton OH, Detroit MI,
Sponsor: Chipscreen Biosciences, Ltd.
Sex: All
Age: 18+
Code: NCT05271292
Phase 1, Phase 2, Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy